Diana Barb1, Fernando Bril1, Srilaxmi Kalavalapalli1, Kenneth Cusi1,2. 1. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida. 2. Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Malcom Randall Veterans Affairs Medical Center, Gainesville, Florida.
Abstract
CONTEXT: The relationship between plasma fibroblast growth factor 21 (FGF21), insulin resistance, and steatohepatitis has not been systematically assessed. OBJECTIVE: To determine if higher plasma FGF21 is associated with worse steatohepatitis on liver biopsy in patients with nonalcoholic fatty liver disease (NAFLD). DESIGN AND SETTING: Cross-sectional study in a university hospital. PATIENTS INTERVENTIONS AND MAIN OUTCOME MEASURES: Patients with a body mass index >25 (n = 187) underwent: (i) euglycemic hyperinsulinemic clamp to assess tissue-specific insulin resistance (IR); (ii) liver magnetic resonance spectroscopy for intrahepatic triglyceride quantification, (iii) liver biopsy (if NAFLD present; n = 146); and (iv) fasting plasma FGF21 levels. METHODS AND RESULTS: Patients were divided into three groups: (i) No NAFLD (n = 41); (ii) No nonalcoholic steatohepatitis (NASH) (patients with isolated steatosis or borderline NASH; n = 52); and (iii) NASH (patients with definite NASH; n = 94). Groups were well-matched for age/sex, prevalence of type 2 diabetes mellitus, and hemoglobin A1c. During euglycemic hyperinsulinemic insulin clamp, insulin sensitivity in skeletal muscle and adipose tissue worsened from No NAFLD to NASH (both P < 0.001). Plasma FGF21 levels correlated inversely with insulin sensitivity in adipose tissue (r = -0.17, P = 0.006) and skeletal muscle (r = -0.23, P = 0.007), but not with liver insulin sensitivity. Plasma FGF21 was higher in patients with NASH (453 ± 262 pg/mL) when compared with the No NASH (341 ± 198 pg/mL, P = 0.03) or No NAFLD (325 ± 289 pg/mL, P = 0.02) groups. Plasma FGF21 increased with the severity of necroinflammation (P = 0.02), and most significantly with worse fibrosis (P < 0.001), but not with worsening steatosis (P = 0.60). CONCLUSIONS: Plasma FGF21 correlates with severity of steatohepatitis, in particular of fibrosis, in patients with NASH. Measurement of FGF21 may help identify patients at the highest risk of disease progression.
CONTEXT: The relationship between plasma fibroblast growth factor 21 (FGF21), insulin resistance, and steatohepatitis has not been systematically assessed. OBJECTIVE: To determine if higher plasma FGF21 is associated with worse steatohepatitis on liver biopsy in patients with nonalcoholic fatty liver disease (NAFLD). DESIGN AND SETTING: Cross-sectional study in a university hospital. PATIENTS INTERVENTIONS AND MAIN OUTCOME MEASURES: Patients with a body mass index >25 (n = 187) underwent: (i) euglycemic hyperinsulinemic clamp to assess tissue-specific insulin resistance (IR); (ii) liver magnetic resonance spectroscopy for intrahepatic triglyceride quantification, (iii) liver biopsy (if NAFLD present; n = 146); and (iv) fasting plasma FGF21 levels. METHODS AND RESULTS: Patients were divided into three groups: (i) No NAFLD (n = 41); (ii) No nonalcoholic steatohepatitis (NASH) (patients with isolated steatosis or borderline NASH; n = 52); and (iii) NASH (patients with definite NASH; n = 94). Groups were well-matched for age/sex, prevalence of type 2 diabetes mellitus, and hemoglobin A1c. During euglycemic hyperinsulinemic insulin clamp, insulin sensitivity in skeletal muscle and adipose tissue worsened from No NAFLD to NASH (both P < 0.001). Plasma FGF21 levels correlated inversely with insulin sensitivity in adipose tissue (r = -0.17, P = 0.006) and skeletal muscle (r = -0.23, P = 0.007), but not with liver insulin sensitivity. Plasma FGF21 was higher in patients with NASH (453 ± 262 pg/mL) when compared with the No NASH (341 ± 198 pg/mL, P = 0.03) or No NAFLD (325 ± 289 pg/mL, P = 0.02) groups. Plasma FGF21 increased with the severity of necroinflammation (P = 0.02), and most significantly with worse fibrosis (P < 0.001), but not with worsening steatosis (P = 0.60). CONCLUSIONS: Plasma FGF21 correlates with severity of steatohepatitis, in particular of fibrosis, in patients with NASH. Measurement of FGF21 may help identify patients at the highest risk of disease progression.
Authors: Lidia S Szczepaniak; Pamela Nurenberg; David Leonard; Jeffrey D Browning; Jason S Reingold; Scott Grundy; Helen H Hobbs; Robert L Dobbins Journal: Am J Physiol Endocrinol Metab Date: 2004-08-31 Impact factor: 4.310
Authors: Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal Journal: Hepatology Date: 2012-06 Impact factor: 17.425
Authors: Amalia Gastaldelli; Kenneth Cusi; Maura Pettiti; Jean Hardies; Yoshinori Miyazaki; Rachele Berria; Emma Buzzigoli; Anna Maria Sironi; Eugenio Cersosimo; Ele Ferrannini; Ralph A Defronzo Journal: Gastroenterology Date: 2007-05-01 Impact factor: 22.682
Authors: Manal F Abdelmalek; Mariana Lazo; Alena Horska; Susanne Bonekamp; Edward W Lipkin; Ashok Balasubramanyam; John P Bantle; Richard J Johnson; Anna Mae Diehl; Jeanne M Clark Journal: Hepatology Date: 2012-07-12 Impact factor: 17.425
Authors: Yasushi Ogawa; Hiroshi Kurosu; Masaya Yamamoto; Animesh Nandi; Kevin P Rosenblatt; Regina Goetz; Anna V Eliseenkova; Moosa Mohammadi; Makoto Kuro-o Journal: Proc Natl Acad Sci U S A Date: 2007-04-23 Impact factor: 11.205
Authors: Kathleen R Markan; Meghan C Naber; Magdalene K Ameka; Maxwell D Anderegg; David J Mangelsdorf; Steven A Kliewer; Moosa Mohammadi; Matthew J Potthoff Journal: Diabetes Date: 2014-07-09 Impact factor: 9.461
Authors: Salah Sommakia; Naredos H Almaw; Sandra H Lee; Dinesh K A Ramadurai; Iosif Taleb; Christos P Kyriakopoulos; Chris J Stubben; Jing Ling; Robert A Campbell; Rami A Alharethi; William T Caine; Sutip Navankasattusas; Guillaume L Hoareau; Anu E Abraham; James C Fang; Craig H Selzman; Stavros G Drakos; Dipayan Chaudhuri Journal: Circ Heart Fail Date: 2021-12-06 Impact factor: 8.790
Authors: Mauy Frujuello Mana; Maria Cândida R Parisi; Maria Lucia Correa-Giannella; Arnaldo Moura Neto; Ademar Yamanaka; Marlone Cunha-Silva; Ana Mercedes Cavaleiro; Cristina Rodrigues Dos Santos; Célia Regina Pavan; Tiago Sevá-Pereira; Sergio S J Dertkigil; Daniel F Mazo Journal: Molecules Date: 2022-05-17 Impact factor: 4.927